KaloBios secures $20 million for drug trials
This article was originally published in Scrip
Executive Summary
KaloBios Pharmaceuticals has raised $20 million to fund several clinical trials of its monoclonal antibodies. The series D round will enable the firm to complete seven Phase I and Phase IIa clinical trials and prepare its candidates KB001 and KB003 for Phase IIb clinical trials.